Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the  FDA Adverse Event Reporting System and literature visualization analysis

ConclusionBased on this pharmacovigilance study,  GLP-1RAs, except albiglutide, are associated with pancreatic carcinoma.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research